for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cardiol Therapeutics Inc

CRDL.OQ

Latest Trade

1.82USD

Change

-0.16(-8.08%)

Volume

46,257

Today's Range

1.80

 - 

1.94

52 Week Range

1.55

 - 

4.96

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.98
Open
1.94
Volume
46,257
3M AVG Volume
6.64
Today's High
1.94
Today's Low
1.80
52 Week High
4.96
52 Week Low
1.55
Shares Out (MIL)
61.92
Market Cap (MIL)
151.71
Forward P/E
-3.89
Dividend (Yield %)
--

Next Event

Cardiol Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Cardiol Therapeutics Announces Pricing Of Public Offering Of Units

Cardiol Therapeutics To Commence Trading On Nasdaq Under Symbol "CRDL"

Cardiol Therapeutics Inc Files For Mixed Shelf Of Up To C$100 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cardiol Therapeutics Inc

Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

Industry

Business Services

Contact Info

602-2265 Upper Middle Road East

OAKVILLE, ON

L6H 0G5

Canada

+1.289.9100850

http://www.cardiolrx.com/

Executive Leadership

Guillermo Torre-Amione

Chairman of the Board

David Elsley

President, Chief Executive Officer, Director

Chris Waddick

Chief Financial Officer, Corporate Secretary

Bernard Lim

Chief Operating Officer

Anthony E. Bolton

Director of Research

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (CAD)

2019

-0.530

2020

-0.690

2021(E)

-0.630
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,926.25
Price To Book (MRQ)
3.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.44
LT Debt To Equity (MRQ)
0.26
Return on Investment (TTM)
-135.46
Return on Equity (TTM)
-124.75

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up